Julia A. O'BRien

Julia A. O'BRien

Auto-generated profile, based on publicly available information

Julia A. O'BRien

University of Pittsburgh

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2022 in Western Journal of Nursing Research
Verified
Journal Article
Closed access
JOJulia A. O’bRien
Julia A. O’bRien
RHRonald L. Hickman
Ronald L. Hickman
CBChristopher Burant
Christopher Burant
MDMary Dolansky
Mary Dolansky
SPSusan Padrino
Susan Padrino
Little is known about the relationships among self-efficacy, social determinants of health, and health outcomes in adults living with sickle cell disease (SCD). We conducted mediation analyses examining the relationships among health literacy, perceived stigma, self-efficacy, and health outcomes in an online cohort of adults living with SCD. The health outcomes explored were physical and mental health-related quality of life (HRQOL) and pain interference; covariates included gender, disease severity, and depressive symptoms. Data came from a cross-sectional, descriptive study of 60 adults with SCD. Perceived stigma and self-efficacy had significant relationships with the study outcomes, while health literacy did not. Self-efficacy partially mediated the relationship between perceived stigma and physical HRQOL, when controlling for depressive symptoms. Future research should investigate the influence of stigma and self-efficacy on health outcomes in patients with SCD and consider stigma when creating interventions to modify self-efficacy.

6 April 2023 in JMIR Mental Health
Verified
Journal Article
Open access
CNCara Nikolajski
Cara Nikolajski
JOJulia O'BRien
Julia O'BRien
ENEmily Nardo
Emily Nardo
ESEva Szigethy
Eva Szigethy
CJCharles Jonassaint
Charles Jonassaint
Background: Depression and other mental health disorders are prevalent among people living with chronic health conditions. Although digital cognitive behavioral therapy (CBT) is considered an effective treatment, African American individuals are less likely to engage in and adhere to digital therapies for mental health disorders compared with White individuals. Objective: The aim of this study was to understand digital CBT mental health treatment perceptions and preferences of African American individuals with sickle cell disease (SCD). Methods: African American individuals with SCD from various US locations were invited to participate in a series of focus groups. Participants were introduced to a health coach–supported mental health app and then asked a series of questions about the usability and appeal of the program as well as, more generally, what would make a digital mental health program effective for them. The authors reviewed the focus group transcripts and conducted a qualitative analysis of the results. Results: A total of 25 people participated in 5 focus groups. Overall, 5 primary themes emerged regarding how app content and related coaching could be modified to enhance digital CBT engagement. These themes included connection with others living with SCD, the personalization of app content and coaching, characteristics of coaches, journaling and pain tracking, and considerations for optimal engagement. Conclusions: Enhancing the user experience by making digital CBT tools relevant to patient populations is critical for optimizing program engagement and its uptake. Our findings highlight potential strategies to modify and design digital CBT tools for users with SCD and may also be applicable to patients with other chronic conditions. Trial Registration: ClinicalTrials.gov NCT04587661; https://clinicaltrials.gov/ct2/show/NCT04587661

3 January 2024 in British Journal of Haematology
Verified
Journal Article
Closed access
CJCharles R. Jonassaint
Charles R. Jonassaint
EPEktha Parchuri
Ektha Parchuri
JOJulia A. O'BRien
Julia A. O'BRien
CLChristina M. Lalama
Christina M. Lalama
JLJonathan Lin
Jonathan Lin
KAKaleab Z. Abebe
Kaleab Z. Abebe

10 December 2022 in Western Journal of Nursing Research
Verified
Journal Article
Closed access
CJCoretta Jenerette
Coretta Jenerette
JOJulia O’bRien
Julia O’bRien
CJCheedy Jaja
Cheedy Jaja
ECEvanilda Souza de Santana Carvalho
Evanilda Souza de Santana Carvalho
CBCheryl Brewer
Cheryl Brewer
RHRonald L. Hickman
Ronald L. Hickman
Health-related stigma, a form of devaluation related to a health condition, is common in individuals with sickle cell disease (SCD). Pain is the hallmark symptom of SCD, and health-related stigma is often described during care-seeking for pain management. Few published instruments measure health-related stigma in individuals with SCD. This study builds on the psychometrics of the 30- and 40-item Sickle Cell Disease Health-Related Stigma Scale (SCD-HRSS). In a sample of 197 adults with SCD, the results support the reliability and validity of a 21-item scale, the SCD-HRSS-Short Form, with an overall Cronbach’s alpha reliability of 0.91 and discriminant validity with the PROMIS-29 subscales (anxiety, depressive symptoms, pain interference, physical fatigue, sleep, and role satisfaction). A shorter yet reliable and valid scale may decrease the burden for this underrepresented, minoritized population while still providing important information regarding their experiences of stigmatization.


17 March 2025 in Journal of Pain and Symptom Management
Verified
Journal Article
Open access
HAHiba Abujaradeh
Hiba Abujaradeh
JOJulia O'BRien
Julia O'BRien
SMSusan R. Mazanec
Susan R. Mazanec
CBCatherine M. Bender
Catherine M. Bender
ISIsabelle M. Schlemmer
Isabelle M. Schlemmer
MRMargaret Rosenzweig
Margaret Rosenzweig
Limited research has examined racial disparities in symptom burden prior to chemotherapy initiation, during and at the chemotherapy completion. To describe and compare the symptom burden (fatigue, pain, and physical functioning) and change over time between Black and White women receiving Early-Stage Breast Cancer (ESBC) chemotherapy while considering social determinants of health. A longitudinal, repeated measures comparative design was employed. Time points of symptom measurement (PROMIS domains) at baseline, mid and end point were adjusted as per patient chemotherapy schedule. Linear mixed models were applied. There were 149 patients, 36% Black 64% White (54 ± 12 years) recommended to receive ESBC chemotherapy with adequate data for symptom analysis. PAIN: Main effect of race was significant (F(1, 390) = 29.43, P < .001) for pain.Black patients experienced significantly higher pain scores compared to White patients at pretherapy (Mean Difference; MD = 3.7, P = .034), midpoint (MD = 5.8, P = .002), and endpoint (MD = 7.8, P < .001). In the adjusted model, Black race and higher BMI were significant predictors of higher pain scores. Black patients experienced significant deterioration in pain over time. The scores for fatigue increased significantly from baseline for Black patients by endpoint (MDT1-T3 = 8.7, P < .001) and for White patients at midpoint (MDT1-T2 = 5.7) and at endpoint (MDT1-T3 = 10.1, P < .001). In the adjusted model, higher BMI predicted worse fatigue scores. Black patients had significantly lower physical function scores compared to White patients at midpoint (MD = 4.0, P = .027). Physical function decreased by endpoint in Black (MDT1-T3 = 7.8, P < .001), and White patients (MDT1-T3 = 7.7, P < .001). In the adjusted model, only higher BMI and cardiopulmonary comorbidities significantly predicted worse physical function. Symptom burden significantly increased over the course of chemotherapy for all patients. Scores for pain and physical function were higher overall for Black patients and deteriorated at a greater rate for Black vs. White women over the course of chemotherapy. BMI was a significant predictor of pain, fatigue, and physical function, this assessment holds implications for proactive assessment and mitigation strategies.